0000899243-19-023677.txt : 20190916
0000899243-19-023677.hdr.sgml : 20190916
20190916195212
ACCESSION NUMBER: 0000899243-19-023677
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190329
FILED AS OF DATE: 20190916
DATE AS OF CHANGE: 20190916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schwartz Jeffrey Lawrence
CENTRAL INDEX KEY: 0001702957
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191095807
MAIL ADDRESS:
STREET 1: C/O BAIN CAPITAL LIFE SCIENCES, LP
STREET 2: 200 CLARENDON STRERET
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-29
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001702957
Schwartz Jeffrey Lawrence
C/O BAIN CAPITAL LIFE SCIENCES INVESTORS
LLC, 200 CLARENDON STREET
BOSTON
MA
02116
1
0
1
0
Stock Option (Right to Buy)
18.00
2019-09-12
4
A
0
29983
0.00
A
2029-09-12
Common Stock
29983
29983
D
Series A Convertible Preferred Stock
2019-03-29
4
A
0
40000000
A
Common Stock
6078103
6078103
I
See footnote
Series B Convertible Preferred Stock
2019-03-29
4
A
0
6931142
A
Common Stock
1053204
1053204
I
See footnote
This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date.
On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, BC SW, L.P. received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
On March 29, 2019, BC SW, L.P. acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer for $1.4428 per share. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
/s/ Jeffery Schwartz
2019-09-16